The company plans to use the funds to develop and complete clinical trials for its regenerative medicine platform, NeoCart. Histogenics plans to list on the NASDAQ under the symbol HSGX. Cowen & Company, Needham and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.
More articles on devices:
aap Implantate receives patent for LOQTEQ
NuVasive COO sells 2.5k shares in $87k transaction
$0.9B by 2019: 3D printing in medical applications market analysis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
